Hypoactive sexual desire disorder (HSDD) is defined as a persistent or recurring deficiency of sexual fantasies, thoughts, and/or receptivity to sexual activity, which causes personal distress. Review of 10 studies conducted between 1978 and 1999 of women in the general population, ages 18 – 75 years suggests the estimated prevalence of HSDD to be 11 – 20% increasing by 2-3% per decade. This prevalence rate is supported in a large general population representative sample (>30,000 responders to 50,000 surveys) using a validated questionnaire to assess low libido (the Changes in Sexual Functioning Questionnaire), and distress (the Female Sexual Distress Scale).
Conflict of Interest: Grants: Biosante Pharmaceuticals, Inc.; Boehringer-Ingelheim; Bristolmyerssquibb; Eli Lilly And Company; Forest Pharmaceuticals; Glaxosmithkline; Neuronetics; Pfizer, Inc.; Sanofi-Aventis; Wyeth Advisory Board/Consultant: Boehringer-Ingelheim; Bristolmyerssquibb; Eli Lilly And Company; Fabre-Kramer Pharmaceuticals; Glaxosmithkline; Novartis Pharmaceuticals; Pfizer, Inc; Vela Pharmaceuticals; Wyeth Speaker’S Bureau/Honorarium: Eli Lilly; Glaxosmithkline; Pfizer, Inc.
Financial Support/Funding: Boehringer-Ingelheim
Sydney Australia, April 2007